Rosa Roman-Carlo, MD
Pulmonary Disease · Mayaguez, PRNPI 1154313849
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 171 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AstraZeneca at 58.2% of the total. 2025 is the largest year on record at $1,103, 3.2 times the $348 reported in 2019.
Across 171 payments — averaging $25.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$730
- Boehringer Ingelheim$346
- United Therapeutics Corporation$209
- PBG Puerto Rico LLC$179
- Merck$88
- plus $255 from 6 others
What the payments were for
- Food & beverage$4,17597%
- Education$1443%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 99 | $2,512 |
| GSK | 34 | $730 |
| Boehringer Ingelheim | 12 | $346 |
| United Therapeutics Corporation | 3 | $209 |
| PBG Puerto Rico LLC | 9 | $179 |
| Merck | 4 | $88 |
| Amgen | 3 | $84 |
| Johnson & Johnson | 2 | $54 |
| Olympus Latin America, Inc. | 1 | $48 |
| Bayer | 2 | $37 |
| Genentech USA, Inc. | 1 | $19 |
| Sanofi | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ANORO ELLIPTA$125
- TEZSPIRE$125
- TYVASO$102
How this compares
$4,319 in reported general payments places this provider in the 70th percentile of 138 pulmonary disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 54 | $699,945 |
| AdempasRiociguat | 43 | $604,529 |
| Spiriva RespimatTiotropium Bromide | 805 | $429,585 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 613 | $301,104 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 415 | $273,991 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 754 | $201,915 |
| Pirfenidone | 91 | $187,401 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 192 | $127,263 |
| FasenraBenralizumab | 22 | $126,280 |
| NucalaMepolizumab | 20 | $73,503 |
| Breo ElliptaFluticasone/Vilanterol | 170 | $70,028 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,561 | $63,172 |
| Wixela InhubFluticasone Propion/Salmeterol | 362 | $59,488 |
| Fluticasone Propionate HfaFluticasone Propionate | 234 | $45,053 |
| SymbicortBudesonide/Formoterol Fumarate | 192 | $44,147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $346 | $1,430,6341,472 claims |
| BayerAdempas | $37 | $604,52943 claims |
| AstraZenecaBreztri Aerosphere, Fasenra, Symbicort, Daliresp, Pulmicort Flexhaler | $2,512 | $458,104666 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta | $730 | $287,580417 claims |
| Johnson & JohnsonXarelto | $54 | $15,89524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 138 pulmonary disease providers in Puerto Rico.
Other pulmonary disease in Mayaguez
- Monica Egozcue DionisiMayaguez$3K
- Danessa Vazquez RamosMayaguez$3K
- Alvaro Aranda RodriguezGuaynabo$725K
- Luis Garcia BarretoCoamo$393K
- Luis Nieves GarrasteguiRio Piedras$121K
- Jahaira Serrano DominguezArecibo$102K
- William Villanueva-BosqueArecibo$67K
- Domingo Chardon FelicianoPonce$45K
- Joel Nieves ScharonSan Juan$43K
- George FahedPonce$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.